WO2014008567A1 - Peptídeo modificado, ligante de receptores cb, kit, processo in vitro para avaliação de ligação a receptores cb, usos, composição farmacêutica para modular a atividade de receptores cb - Google Patents
Peptídeo modificado, ligante de receptores cb, kit, processo in vitro para avaliação de ligação a receptores cb, usos, composição farmacêutica para modular a atividade de receptores cb Download PDFInfo
- Publication number
- WO2014008567A1 WO2014008567A1 PCT/BR2013/000251 BR2013000251W WO2014008567A1 WO 2014008567 A1 WO2014008567 A1 WO 2014008567A1 BR 2013000251 W BR2013000251 W BR 2013000251W WO 2014008567 A1 WO2014008567 A1 WO 2014008567A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- asp
- amino acid
- tail
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
Definitions
- the present invention is in the fields of pharmacy, medicine, chemistry and biotechnology. More specifically, the present invention describes a novel modified peptide that acts as a cannabinoid receptor (CB) ligand, especially CB1 and / or CB2, and / or modulator of its activity; Also described is an in vitro kit and method for evaluating CB receptor binding, uses and pharmaceutical composition for modulating CB receptor activity.
- CBD cannabinoid receptor
- the cannabinoid system which comprises cannabinoid receptors (CB), CB1 and CB2 and their endogenous ligands, acts to control food intake and energy metabolism and is widely expressed in the brain, including cortex, hippocampus, amygdala, pituitary and hypothalamus. .
- CB receptors, particularly CB1 have been identified in numerous peripheral organs and tissues, including thyroid gland, adrenal gland, reproductive organs, adipose tissue, liver, muscles, and gastrointestinal tract.
- the present invention describes a novel unnatural peptide which yields surprising results as to its activity, more especially as to its use and / or its cannabinoid receptor modulating activity.
- the peptide of the present invention additionally has the advantage that it is particularly useful for modulating CB receptor activity and for treating metabolic disorders such as for reducing obesity, while still having the additional advantage of not crossing the blood-brain barrier. as shown by research results made by inventors.
- WO 2011/01 847 discloses the use of hemopressin for the treatment of obesity in an individual and it is further disclosed that hemopressin is a compound that binds effectively to the CB1 receptor and does not cross the blood brain barrier.
- the present invention differs from that document, among other reasons, for presenting a new unnatural peptide derived from angiotensin-converting enzymes. Therefore, the peptide of the invention is not at all similar to hemopressin.
- the results of tests performed by the inventors were surprising, especially in relation to interaction with cannabinoid receptors, facts not described or suggested in the document.
- the present invention provides a novel unnatural peptide, which among other functions and uses is CB receptor binder and which does not have the drawbacks of interaction with the blood brain layer - and which additionally provides several useful technical effects.
- a novel unnatural peptide of sequence SeqID: 1 and / or sequence with at least 70% similarity to it is disclosed in the present invention.
- the unnatural peptide of the invention is particularly useful as a cannabinoid receptor binder and / or as a modulator of CB receptor activity.
- the unnatural peptide of the invention in addition to being generally a binder superior to those known in the art, does not interact with the blood-brain barrier, providing additional advantages in the therapeutic use of mammals.
- the present invention solves a number of problems known in the art such as providing: a novel unnatural peptide; a cannabinoid receptor ligand; an in vitro kit and method for the evaluation of cannabinoid receptor receptor binding; a molecular entity that provides these technical effects without passing through the blood-brain barrier; and providing novel therapeutic alternatives for treating metabolic disorders and / or obesity.
- the present invention further discloses, among others, the use of said unnatural peptide for the preparation of medicaments; and a pharmaceutical composition for modulating CB receptor activity, thus being useful in the treatment of metabolic disorders and / or to promote aesthetic weight reduction.
- modified unnatural peptide comprising a sequence at least 70% similar to the peptide AA 1 -Asp-AA 2 -Aa2-Ala-Asp-Asp-AA 3 -AA4 in what:
- AAi is a tail of 0-10 amino acids
- AA2 is a hydrophobic amino acid
- AA3 is a charged amino acid
- AA4 is a tail of 0 - 13 amino acids.
- said modified peptide comprises at least 90% similarity to the SeqID: 1 (or also referred to as Pep 19) amino acid sequence.
- the AA4 amino acid tail is a functionalized tail.
- said tail is a 10 amino acid TAT tail.
- the hydrophobic amino acid AA2 is selected from the group consisting of: alanine, isoleucine, leucine, phenylalanine, valine, proline, glycine, or combinations thereof.
- the AA 3 charged amino acid is selected from the group consisting of: arginine, lysine, aspartic acid, glutamic acid, or combinations thereof.
- AA 4 is the amino acid tail with 0 amino acid or amino acid AA4 comprises a tail sequence containing the amino acids proline, leucine and / or threonine.
- the peptide is selected from: Seq ID: 1, Seq ID: 2, Seq ID: 3, Seq ID: 4, Seq ID: 5, Seq ID: 6 or combinations thereof.
- the cyclic peptide is in the cyclic form of the amino acid sequences SeqID: 1, SeqID: 2, SeqID: 3, SeqID: 4, and / or SeqID: 6.
- Another object of the present invention is a CB receptor binder, said binder consisting of at least one unnatural peptide comprising at least 70% similarity to the peptide AArAsp-AA 2 -AA 2 - Ala-Asp-Asp-AAa-AA -have to:
- AA ⁇ tail is between 0-10 amino acids
- AA 2 is a hydrophobic amino acid
- AA 3 is a charged amino acid
- ⁇ , ⁇ is a tail of 0 - 13 amino acids.
- said binder is a CB agonist, antagonist or inverse agonist.
- said binder is a CB1 agonist, antagonist or inverse agonist and / or a CB2 receptor agonist, antagonist or inverse agonist.
- the binder is selected from: Seq ID: 1, Seq ID: 2, Seq ID: 3, Seq ID: 4, Seq ID: 5, Seq ID: 6 or their cyclic forms and / or combinations thereof.
- Other objects of the present invention are also an in vitro kit and method for the evaluation of CB receptor binding. Said process comprises at least one step of contacting a CB receptor-containing biological sample with at least one unnatural peptide comprising at least 70% similarity to the AAi-Asp-AA 2 -AA 2 -Ala-Asp-Asp-peptide.
- AAi is a tail of 0-10 amino acids
- AA 2 is a hydrophobic amino acid
- AA3 is a charged amino acid
- AA4 is a tail of 0 - 13 amino acids.
- the unnatural peptide and / or binder of the kit or process of the invention is chemically modified to facilitate detection / localization of CB receptor (s).
- said chemical modification involves the inclusion in a region of the peptide / binder of one or more chromophores and / or radiative element (s).
- said in vitro kit or process provides selective binding of CB receptors (CB1 and / or CB2, for example), quantitation of expression level of such receptors and / or quantification of peptide binding intensity. / CB receptor ligand, as well as the biological activity of the receptor.
- Said in vitro kit or process is particularly useful for detecting other CB receptor-binding molecular entities, or even molecular entities that affect the selective or non-selective binding of the peptides of the invention to CB receptors.
- kits or processes are also particularly useful for the subsequent customization of therapeutic treatments based on pharmaceutical compositions comprising the unnatural peptide of the invention.
- the kit or method of the invention is therefore applicable to the therapeutic prediction / prognosis of the evolution of metabolic conditions / disorders, or even the potential therapeutic success in the treatment of: metabolic disorders comprising obesity, diabetes, hypertension. systemic arterial disease (or related disease, condition, and / or comorbidities); overweight prevention; appetite regulation; satiety induction; weight gain prevention after successful weight loss; increased energy consumption; aesthetic weight reduction; or bulimia.
- AAi is a tail of 0-10 amino acids
- AA2 is a hydrophobic amino acid
- AA3 is a charged amino acid
- AA4 is a tail of 0 - 13 amino acids
- said use is one or more unnatural peptides selected from: SeqID: 1, SeqID: 2, SeqID: 4, SeqID: 5, SeqID: 6 or cyclic forms thereof, and / or combinations thereof.
- Another object of the invention is a pharmaceutical composition for modulating CB receptor activity in a mammal, said composition comprising: a pharmaceutically acceptable carrier; and, as active ingredient, one or more unnatural peptides comprising at least 70% similarity to the AArAsp-AA 2 -AA 2 -Ala-Asp-Asp-AA3-AA4 peptide, wherein:
- AAi is a tail of 0-10 amino acids
- AA 2 is a hydrophobic amino acid
- AA3 is a charged amino acid
- AA is a tail of 0 - 13 amino acids.
- said pharmaceutical composition further comprises other active ingredients.
- the pharmaceutical composition is in tablet, gel, solution for injection or inhalable forms or as an adhesive.
- Figure 1 shows a screening of new ligands for the receptor.
- Figure 2 shows pain test results following administration of a preferred peptide embodiment of the invention (SeqID: 1) compared to other peptides known in the art.
- Figure 3 shows results of depression (forced swimming) tests following administration of a preferred peptide embodiment of the present invention (SeqID: 1) compared to other peptides of the art.
- Figure 4 shows results of retroperitoneal adipose tissue measurement tests following administration of a preferred peptide embodiment of the present invention (SeqID: 1).
- Figure 5 shows results of inguinal adipose tissue measurement tests following administration of a preferred peptide embodiment of the present invention (SeqID: 1).
- Figure 6 shows results of gonadal adipose tissue measurement tests following administration of a preferred peptide embodiment of the present invention (SeqID: 1).
- Figure 7 shows results of mesenteric adipose tissue measurement tests following administration of a preferred peptide embodiment of the present invention (SeqID.1).
- Figure 8 shows results of brown adipose tissue measurement tests following administration of a preferred peptide embodiment of the present invention (SeqID: 1).
- Figure 9 shows results of adiposity index measurement following administration of a preferred peptide embodiment of the present invention (SeqID: 1).
- Figure 10 shows the experimental results on CB1 receptors for another preferred peptide embodiment of the present invention (SeqID: 2) and comparison to control and SeqID: 1.
- Figure 11 shows the experimental results on CB2 receptors for another preferred peptide embodiment of the present invention (SeqID: 2) and comparison to control and SeqID: 1.
- Figure 12 shows the experimental results on CB1 receptors for another preferred peptide embodiment of the present invention (SeqID: 3) and comparison to control and SeqID: 1.
- Figure 13 shows the experimental results on CB1 receptors for another preferred peptide embodiment of the present invention (SeqID: 4) and comparison to control and SeqID: 1.
- Figure 14 shows experimental results on CB1 receptors for another preferred peptide embodiment of the present invention (SeqID: 5) and comparison to control and SeqID: 1.
- Figure 15 presents the experimental results on retroperitoneal adipose tissue for a preferred peptide embodiment of the present invention (SeqID: 1) and comparison to control and Rimonabant.
- Figure 16 shows the experimental results in gonadal adipose tissue for a preferred peptide embodiment of the present invention (SeqID: 1) and comparison to control and Rimonabant.
- Figure 17 shows the experimental results in inguinal adipose tissue for a preferred peptide embodiment of the present invention (SeqID: 1) and comparison to control and Rimonabant.
- Figure 18 shows the experimental results on brown adipose tissue for a preferred peptide embodiment of the present invention (SeqID: 1) and comparison to control and rimonabant.
- Figure 19 shows the experimental results in mesenteric adipose tissue for a preferred peptide embodiment of the present invention (SeqID: 1) and comparison to control and rimonabant.
- Figure 20 presents the experimental results related to the adiposity index for a preferred peptide embodiment of the present invention (SeqID: 1) and comparison to control and rimonabant.
- Figure 21 shows the experimental results on serum leptin concentration for a preferred peptide embodiment of the present invention (SeqID: 1) and comparison to control and rimonabant.
- Figure 22 shows the experimental results on protein expression of CB1 and CB2 in brown adipose tissue for a preferred peptide embodiment of the present invention (SeqID: 1) and comparison to control and rimonabant.
- Figure 23 shows the experimental results with respect to the weight of animals supplemented with 20% sucrose for a preferred peptide embodiment of the present invention (SeqID: 1) and comparison to control and rimonabant.
- Figure 24 shows the experimental glycemic results of animals supplemented with 20% sucrose for a preferred peptide embodiment of the present invention (SeqID: 1) and comparison to control and rimonabant.
- Figure 25 shows the experimental insulinemia results of animals supplemented with 20% sucrose for a preferred peptide embodiment of the present invention (SeqlD: 1) and compared to control and Rimonabant.
- Figure 26 shows the experimental results regarding cholesterol levels of animals supplemented with 20% sucrose for a preferred peptide embodiment of the present invention (SeqID: 1) and comparison to control and rimonabant.
- Figure 27 shows the experimental results with respect to triglyceride levels of animals supplemented with 20% sucrose for a preferred peptide embodiment of the present invention (SeqID: 1) and comparison to control and rimonabant.
- Figure 28 shows the experimental results with respect to the amount of gonadal adipose tissue of the animals supplemented with 20% sucrose for a preferred peptide embodiment of the present invention (SeqID: 1) and comparison to control and rimonabant.
- Figure 29 shows the experimental results with respect to the amount of mesenteric adipose tissue from animals supplemented with 20% sucrose for a preferred peptide embodiment of the present invention (SeqID: 1) and comparison to control and rimonabant.
- Figure 30 shows the experimental results with respect to the amount of brown adipose tissue from animals supplemented with 20% sucrose for a preferred peptide embodiment of the present invention (SeqID: 1) and comparison to control and rimonabant.
- Figure 31 presents the experimental results with respect to the amount of retroperitoneal adipose tissue from animals supplemented with 20% sucrose for a preferred peptide embodiment of the present invention (SeqID: 1) and comparison to control and rimonabant.
- Figure 32 presents the experimental results with respect to the amount of inguinal adipose tissue of animals supplemented with 20% sucrose for a preferred peptide embodiment of the present invention (SeqID: 1) and comparison to control and rimonabant.
- Figure 33 presents the experimental results regarding the adiposity index of the animals supplemented with 20% sucrose for a preferred embodiment of peptide of the present invention (SeqID: 1) and comparison to control and Rimonabant.
- Figure 34 shows the experimental results with respect to the adiposity index of animals supplemented with 20% sucrose for a preferred peptide embodiment of the present invention (SeqID: 1) and comparison to control and rimonabant.
- Figure 35 shows the experimental blood pressure results of animals supplemented with 20% sucrose for a preferred peptide embodiment of the present invention (SeqID: 1) and comparison to control and rimonabant.
- the inventive concept common to the various objects of the invention is to provide an unnatural peptide useful as a CB receptor binder. From this inventive concept, various applications have been realized by the inventors using said inventive concept, including but not limited to: selective or non-selective modulation of the activity of such receptors; obtaining an in vitro kit and method for assessing CB receptor binding; use of said peptide as an aid in identifying other CB binding molecular entities or interfering with the binding of the peptide of the invention to CB receptors; the use of said peptide for the preparation of pharmaceutical composition to modulate CB receptor activity.
- modified peptide is to be understood as an unnatural peptide, artificially modified in order to achieve the objects of the present invention.
- At least 70% similarity shall be understood to mean maintaining at least 70% similarity and / or identity with the (SeqlD: 1) peptide. In the context of present peptide, this would be the same as modifying up to 3 amino acids such that the peptide retains the same activity presented throughout that patent application.
- cyclic or" circular “peptide” is meant to be a peptide that has had a covalent bond between the two ends of a linear nucleic acid molecule (single or double stranded) involving the union of 3 5'-hydroxyl to 5'-phosphate by any method known in the art, particularly by the activity of ligase enzymes.
- the cyclic peptide may be used in place of the linear peptide because it is more difficult to degrade because its hydrolysing enzyme attack ends or zones are not as exposed as in a linear peptide.
- CB receptor binder is meant as a compound or molecule that interacts with the CB system and / or CB1 or CB2 receptors in order to promote any direct or indirect binding effect to said receptors.
- agonist is to be understood as a drug, drug, hormone, neurotransmitter or other signaling molecule that forms a complex with a receptor site, thereby triggering an active response from a cell.
- inverse agonist or antagonist is understood to mean an agent (s) (eg, drugs, drugs, hormones or enzymes) that binds to agonist receptors and produces pharmacological effects opposite to those of agonists, such that the action of one partially or totally inhibits the effect of the other.
- a compound will be an inverse agonist when acting in the presence of an agonist, but by reducing its activity, an antagonist will be a compound that will totally block agonist activity.
- modulating CB receptor function should be understood as an interaction that results in alteration of the biochemical activity of the CB receptor, particularly CB1 or CB2. It is understood that the change is positive when an antagonist or inverse agonist effect occurs on CB receptors and that the change is negative when an agonist effect occurs on CB receptors.
- composition means any composition containing an active ingredient for prophylactic, palliative and / or curative purposes, acting to maintain and / or restore homeostasis and may be administered topically, parenterally, enterally and / or intrathecal.
- pharmaceutically acceptable formulation is meant a formulation containing pharmaceutically acceptable excipients and carriers well known to those skilled in the art, such as the development of suitable doses and treatments for use in particular compositions which may be described. in a series of treatment regimens including oral, parenteral, intravenous, intranasal, intravitreal and intramuscular, intracerebral, intracerebroventricular and intraocular and their administration and / or formulation.
- metabolic disorders should be understood as any metabolic disorder that alters the normal physiological functions of a living being, especially mammals.
- the term includes chronic and acute diseases that cause physiological changes in humans, such as: dyslipidemias of various causes, obesity, hypertension, diabetes mellitus, type 1 diabetes, metabolic syndrome, atherosclerosis, among other disorders.
- metabolic The present invention discloses, among other objects, an unnatural peptide comprising at least 70% similarity to the AA Asp-AA2-AA 2 -Ala-Asp-Asp-AA3-AA4 peptide, wherein:
- AAi is a tail of 0-10 amino acids
- AA2 is a hydrophobic amino acid
- AA 3 is a charged amino acid
- AA4 is a tail of 0 - 13 amino acids.
- the modified unnatural peptide has functionalized AA1 amino acid tail.
- the modified unnatural peptide has the hydrophobic amino acid AA2 selected from the group consisting of: alanine, isoleucine, leucine, phenylalanine, valine, proline, glycine, or combinations thereof.
- the modified unnatural peptide has the AA 3 charged amino acid selected from the group consisting of: arginine, lysine, aspartic acid, glutamic acid, or combinations thereof.
- the modified unnatural peptide has the 0 amino acid AA4 amino acid tail, or the AA4 amino acid tail comprising a sequence containing the amino acids proline, leucine and / or threonine.
- the modified unnatural peptide has at least
- the modified unnatural peptide is selected from the sequence peptides: SeqID: 1; SeqID: 2; SeqID: 3; Seq ID: 4; SeqID: 5; Seq ID: 6; its cyclic forms; or combinations thereof
- the present invention also provides an in vitro kit and method for the evaluation of CB receptor binding. Said process comprises at least one step of contacting a biological sample containing a CB receptor with at least one unnatural peptide of the invention.
- the unnatural peptide and / or binder of the kit or process of the invention is chemically modified to facilitate CB receiver (s) detection / localization.
- said chemical modification involves the inclusion in a region of the peptide / binder of one or more chromophores and / or radiative element (s).
- Said in vitro kit or process provides selective binding of CB receptors (for example CB1 and / or CB2), quantitation of expression level of such receptors and / or quantitation of peptide / ligand binding intensity to CB receptors. .
- Said in vitro kit or process is particularly useful for detecting other CB receptor-binding molecular entities, or even molecular entities that affect the selective or non-selective binding of the peptides of the invention to CB receptors.
- kits or processes are also particularly useful for the subsequent customization of therapeutic treatments based on pharmaceutical compositions comprising the unnatural peptide of the invention.
- the kit or method of the invention is therefore applicable to the therapeutic prediction / prognosis of the evolution of metabolic conditions / disorders, or even potential therapeutic success in the treatment of: metabolic disorders comprising obesity, diabetes, systemic arterial hypertension (or disease, related condition). and / or associated comorbidities); overweight prevention; appetite regulation; satiety induction; weight gain prevention after successful weight loss; increased energy consumption; aesthetic weight reduction; or bulimia.
- the peptide of the invention has several applications, being particularly useful, among other applications, for modulating CB receptor activity, being useful for the treatment of metabolic conditions or diseases associated with modulation of cannabinoid receptor (CB) activity - without adverse effects. undesirable effects known from those available in the prior art.
- the peptide of the invention is particularly useful as a CB1 and / or CB2 antagonist or inverse agonist, acting superior to those available in the art and not crossing the blood-brain barrier.
- the peptide of the invention is orally administrable to a mammal, ie does not degrade during oral ingestion. This feature is particularly unexpected since an individual's natural enzymes do not degrade or degrade the peptide very little when in the digestive tract and it acts effectively when administered orally.
- the present patent application discloses a pharmaceutical composition comprising the peptide of the present patent application.
- the present pharmaceutical composition comprises a pharmaceutically acceptable carrier and may additionally comprise other active and / or pharmaceutically acceptable salts thereof, said peptide being the active component of the composition, which is administered in tablet, gel, solution for injection or other forms of administration. administration suitable for pharmaceutical and medical purposes.
- the peptide of the present patent application acts as a CB1 receptor binder and, more preferably, said peptide is CB1 agonist, antagonist or inverse agonist.
- the peptide of the present patent application acts as a CB2 agonist, antagonist or inverse agonist.
- the peptide of the present patent application is also useful for the preparation of medicaments for the treatment of atherosclerosis, hypertension, diabetes, type 2 diabetes, impaired glucose tolerance (ITG), dyslipidemia, coronary heart disease, gallbladder disease, stone. in the gallbladder, osteoartitis, cancer, sexual dysfunctions and risks of premature death.
- the peptide of the invention is also useful for preparing a medicament for promoting aesthetic weight reduction in an individual.
- anesthesia weight loss is meant the weight loss of an individual who has no medical indication for reducing it. your body mass.
- the present peptide is orally administrable to a mammal, ie, does not degrade during oral ingestion. This feature is particularly unexpected since an individual's natural enzymes do not degrade or degrade the peptide very little when in the digestive tract and it acts effectively when administered orally.
- the peptide has sequence Asp-lle-lle-Ala-Asp-Asp-Glu-Pro-Leu-Thr (indicated in amino acid sequence SeqlD: 1 or Pep 19 and identified with the GPCR screening method. ) and provided action as CB1 receptor inverse agonist.
- Figure 1 demonstrates said CB1 receptor ligand by ELISA with stirate membranes (5 g / well) treated with 1 cada of each drug for 2 hours at room temperature and incubated with anti-CB1 antibody (1: 500). .
- Figure 3 presents the effects of the application of the peptide of the present invention in a depression model (forced swimming) and it was found that the Peptide, unlike rimonabant, does not cause depression.
- Forced swimming testing was performed based on prior testing ([Harkin et al., 2004], [Petit-Demouliere et al., 2005] and [Treit and Menard, 1998]).
- the rats were placed in a pool with water (24 + -1 ° C) up to 1m from the bottom (so that the rat cannot touch the bottom) and 20cm from the pool the immobility time (when the animal does not move except small movements necessary for its floating); The procedure was recorded by 3 experiments after 1, 6 and 9 minutes.
- the present peptide has activity even when administered orally. This fact is difficult to occur in the art and has several advantages in terms of pharmaceutical and commercial administration of a drug.
- the peptide has sequence Asp-lle-Leu-Ala-Asp-Asp-Glu-Pro-Leu-Thr (indicated in SeqlD: 2 amino acid sequence and identified with the GPCR screening method) and provided CB2 receptor inverse agonist action ( Figures 10 and 11).
- the present peptide has activity even when administered orally. This fact is difficult to occur in the art and has several advantages in terms of pharmaceutical and commercial administration of a drug.
- the peptide has sequence Asp-lle-lle-Ala-Asp-Asp-Ala-Pro-Leu-Thr (indicated in amino acid sequence SeqlD: 3 and identified with the GPCR screening method) and provided lower activity at CB1 receptors (Figure 12) in relation to the activity obtained by the amino acid sequence SeqlD: 1. However, the pharmacological effect was maintained.
- the present peptide has activity even when administered orally. This fact is difficult to occur in the art and has several advantages in terms of pharmaceutical and commercial administration of a drug.
- the peptide has Asp-lle-lle-Ala-Asp-Asp-Glu sequence (indicated in the SeqlD: 4 amino acid sequence and identified with the GPCR screening method) and provided enhanced inverse agonist activity in CB1 receptors, when compared to the activity obtained with the sequence SeqlD: 1.
- the seven amino acids of this sequence are essential for peptide activity as an inverse agonist in CB1.
- the peptide has sequence Asp-lle-lle-Ala-Asp-Asp-Glu-Ala-Leu-Thr (indicated in amino acid sequence SeqlD: 5 and identified with the GPCR screening method) and provided , at low doses, inverse agonist activity and, at high doses, showed agonist activity at endocannabinoid receptors.
- the present peptide has activity even when administered orally. This fact is difficult to occur in the art and has several advantages in terms of pharmaceutical and commercial administration of a drug.
- the peptide is cyclic, has sequence Asp-lle-lle-Ala-Asp-Asp-Glu-Pro-Leu-Thr (indicated in amino acid sequence SeqlD: 5 but identified by the screening method). GPCR) and provided similar biological activity when compared to to the same non-cyclic peptide.
- cyclization is interesting especially with regard to the increase in peptide half-life in the body (in vivo). It has also been found that the present peptide has activity even when administered orally. This fact is difficult to occur in the art and has several advantages in terms of pharmaceutical and commercial administration of a drug.
- Table 1 summarizes the data from test results made with the peptide of the invention in several of its preferred embodiments, in stark contrast to the results of using the natural peptide known in the prior art.
- DIIADDE Peptide Increases peptide activity as Modified 3 activity in
- Position 8 is an agonist component of the peptide since
- DIIADDEPLT Peptide No major difference was detected in vivo, by Modified 5 (cyclic) change in change in sock time (Seq ID 5) peptide life activity.
- modified peptide 6 (SeqlD: 6), although their tests have not shown detectable activity against CB1 or CB2, may be useful in combinations with other modified peptides indicated above in kits for evaluation of possible substrate competition and evaluation. of other effects.
- Figure 15 presents the effects of applying a preferred peptide embodiment of the present invention (SeqID: 1 or Pep 19) on a retroperitoneal adipose tissue model where lean wistar rats were treated with a dose of Rimonabant (100 ⁇ g / kg) or peptide 19 (Pep 19 100 ⁇ g / kg) for 3 days orally.
- the measurement of adipose tissue was made after the end of treatment.
- Results indicate that the retroperitoneal adipose tissue mass was lower in the animals receiving Pep 19 compared to the groups receiving rimonabant and / or saline.
- Figure 16 shows the effects of applying a preferred peptide embodiment of the present invention (SeqID: 1 or Pep 19) on a gonadal adipose tissue model where lean Wistar rats were treated with a dose of Rimonabant (100 ⁇ g / kg) or peptide 19 (Pep 19 100 ⁇ g / kg) for 3 days orally.
- the measurement of adipose tissue was made after the end of treatment.
- Figure 17 shows the effects of applying a preferred peptide embodiment of the present invention (SeqID: 1 or Pep 19) in an inguinal adipose tissue model where lean Wistar rats were treated with a dose of Rimonabant (100 ⁇ g / kg) or peptide 19 (Pep 19 100 ⁇ g / kg) for 3 days orally.
- Results indicate that the mass of inguinal adipose tissue was smaller in the animals receiving Pep 19 compared to the groups receiving rimonabant and / or saline.
- Figure 18 shows the effects of applying a preferred embodiment of peptide of the present invention (SeqID: 1 or Pep 19) to a brown adipose tissue model where lean Wistar rats were treated with a dose of Rimonabant (100 ⁇ g / kg) or peptide 19 (Pep 19 100 ⁇ g / kg) for 3 days orally.
- Results indicate that brown adipose tissue mass was lower in animals receiving Pep 19 compared to groups receiving rimonabant and / or saline.
- Results indicate that there is no difference in mesenteric adipose tissue mass between the animals receiving Pep 19 compared to the groups receiving rimonabant and / or saline.
- Figure 20 shows the effects of applying a preferred peptide embodiment of the present invention (SeqID: 1 or Pep 19) on animal adiposity index.
- Lean wistar rats were treated with a dose of Rimonabant (100 ⁇ g / kg) or peptide 19 (Pep 19 100 ⁇ g / kg) for 3 days orally.
- Figure 21 shows the effects of applying a preferred peptide embodiment of the present invention (SeqID: 1 or Pep 19) on animal serum leptin concentration.
- Lean wistar rats were treated with a dose of Rimonabant (100 ⁇ g / kg) or peptide 19 (Pep 19 100 ⁇ g / kg) for 3 days orally.
- Figure 22 shows the effects of applying a preferred peptide embodiment of the present invention (SeqID: 1 or Pep 19) on protein expression of CB1 and CB2 in brown adipose tissue of animals.
- Figure 23 shows the effects of applying a preferred peptide embodiment of the present invention (SeqID: 1 or Pep 19) on the weight of animals supplemented with 20% sucrose.
- Example 16 Weight Determination of Animals Supplemented with 20% Sucrose
- Figure 24 shows the effects of applying a preferred peptide embodiment of the present invention (SeqID: 1 or Pep 19) on the glycemia of animals supplemented with 20% sucrose.
- Wistar rats fed a standard diet supplemented with 20% sucrose in drinking water were used for 60 days prior to and during the 30-day treatment with SALINA (negative control), Rimonabant (positive control), Peptide 19 (Pep 19) in concentration. 50 g / kg and Peptide 19 (Pep 19) at a concentration of 100 g / kg.
- Example 17 Determination of Insulinemia of Animals Supplemented with 20% Sucrose
- Figure 25 shows the effects of applying a preferred peptide embodiment of the present invention (SeqID: 1 or Pep 19) on insulinemia of animals supplemented with 20% sucrose.
- Wistar rats fed a standard diet supplemented with 20% sucrose in drinking water were used for 60 days before and during the 30-day treatment with SALINA (negative control), Rimonabant (positive control), Peptide 9 (Pep 9) in concentration. 50 g / kg and Peptide 19 (Pep 19) at a concentration of 100 g / kg.
- Results indicate that animals treated with Peptide 19 at 100 pg / kg presented the lowest average insulinemia after 30 days of treatment.
- Example 18 Determination of Cholesterol of Animals Supplemented with 20% Sucrose
- Figure 26 shows the effects of applying a preferred peptide embodiment of the present invention (SeqID: 1 or Pep 19) on the cholesterol levels of animals supplemented with 20% sucrose.
- Results indicate that animals treated with Rimonabant (positive control), Peptide 19 at concentrations of 100 and 50 g / kg presented the lowest percentages of cholesterol after 30 days of treatment.
- Figure 27 shows the effects of applying a preferred peptide embodiment of the present invention (SeqID: 1 or Pep 19) on the triglyceride levels of animals supplemented with 20% sucrose.
- Wistar rats fed a standard diet supplemented with 20% sucrose in drinking water were used for 60 days prior to and during the 30-day treatment with SALINA (negative control), Rimonabant (positive control), Peptide 19 (Pep 19) in concentration. 50pg / kg and Peptide 19 (Pep 19) at a concentration of 100 pg / kg.
- Figure 28 shows the effects of applying a preferred peptide embodiment of the present invention (SeqID: 1 or Pep 19) on the amount of gonadal adipose tissue of animals supplemented with 20% sucrose.
- Figure 29 shows the effects of applying a preferred peptide embodiment of the present invention (SeqID: 1 or Pep 19) on the amount of mesenteric adipose tissue of animals supplemented with 20% sucrose.
- Wistar rats fed a standard diet supplemented with 20% sucrose in drinking water were used for 60 days prior to and during the 30-day treatment with SALINA (negative control), Rimonabant (positive control), Peptide 19 (Pep 19) in concentration. 50pg / kg and Peptide 19 (Pep 19) at a concentration of 100 pg / kg.
- Figure 30 shows the effects of applying a preferred peptide embodiment of the present invention (SeqID: 1 or Pep 19) on the amount of brown adipose tissue of animals supplemented with 20% sucrose.
- Figure 31 shows the effects of applying a preferred peptide embodiment of the present invention (SeqID: 1 or Pep 19) on the amount of retroperitoneal adipose tissue of animals supplemented with 20% sucrose.
- Example 24 Determination of Amount of Inguinal Adipose Tissue of Animals Supplemented with 20% Sucrose
- Figure 32 shows the effects of applying a preferred peptide embodiment of the present invention (SeqID: 1 or Pep 19) on the amount of inguinal adipose tissue of animals supplemented with 20% sucrose.
- Figure 33 shows the effects of applying a preferred peptide embodiment of the present invention (SeqID: 1 or Pep 19) on the adiposity index of animals supplemented with 20% sucrose.
- Wistar rats fed a standard diet supplemented with 20% sucrose in drinking water were used for 60 days prior to and during the 30-day treatment with SALINA (negative control), Rimonabant (positive control), Peptide 19 (Pep 19) in concentration. 50pg / kg and Peptide 19 (Pep 19) at a concentration of 100 pg / kg.
- Example 26 Determination of Adiposity Index of 20% Sucrose Supplemented Animals
- Figure 34 shows the effects of applying a preferred peptide embodiment of the present invention (SeqID: 1 or Pep 19) on the adiposity index of animals supplemented with 20% sucrose.
- Wistar rats fed a standard diet supplemented with 20% sucrose in drinking water were used for 60 days prior to and during the 30-day treatment with SALINA (negative control), Rimonabant (positive control), Peptide 19 (Pep 19) in concentration. 100 g / kg, 300 g / kg and 600 g / kg.
- Figure 35 shows the effects of applying a preferred peptide embodiment of the present invention (SeqID: 1 or Pep 19) on the blood pressure of animals supplemented with 20% sucrose.
- Wistar rats fed a standard diet supplemented with 20% sucrose in drinking water were used for 60 days prior to and during the 30-day treatment with SALINA (negative control), Rimonabant (positive control), Peptide 19 (Pep 19) in concentration. 100pg / Kg, 300pg / Kg and 600pg / Kg.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Anesthesiology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13816344.9A EP2878306B1 (en) | 2012-07-13 | 2013-07-12 | Modified peptide, cb receptor ligand, kit, in vitro process for evaluating cb receptor bonds, uses, pharmaceutical composition for modulating cb receptor activity |
CN201380047844.5A CN104619333B (zh) | 2012-07-13 | 2013-07-12 | 经修饰的肽,cb受体的配体,用于评估与cb受体结合的试剂盒、体外方法,用于调节cb受体活性的药物组合物、用途 |
US14/412,781 US9796760B2 (en) | 2012-07-13 | 2013-07-12 | Modified peptide, CB receptor ligand, kit in vitro process for evaluating CB receptor bonds, uses, pharmaceutical composition for modulating CB receptor activity |
DK13816344.9T DK2878306T3 (en) | 2012-07-13 | 2013-07-12 | MODIFIED PEPTIDE, CB RECEPTOR LIGAND, KIT, IN VITRO PROCEDURE FOR EVALUATION OF CB RECEPTOR BINDINGS, APPLICATIONS, PHARMACEUTICAL COMPOSITION FOR MODULATING CBRECEPTOR ACTIVITY |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRBR102012017421-9A BR102012017421A2 (pt) | 2012-07-13 | 2012-07-13 | Peptídeo, composicão farmacêutica, ligante de receptor cb, metodo para modular a funcao de receptor cb, uso, método para o tratamento de obesidade, e, método para promover a redução de peso estetica em um indivíduo |
BRBR1020120174219 | 2012-07-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014008567A1 true WO2014008567A1 (pt) | 2014-01-16 |
Family
ID=49915273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BR2013/000251 WO2014008567A1 (pt) | 2012-07-13 | 2013-07-12 | Peptídeo modificado, ligante de receptores cb, kit, processo in vitro para avaliação de ligação a receptores cb, usos, composição farmacêutica para modular a atividade de receptores cb |
Country Status (4)
Country | Link |
---|---|
US (1) | US9796760B2 (pt) |
CN (1) | CN104619333B (pt) |
BR (1) | BR102012017421A2 (pt) |
WO (1) | WO2014008567A1 (pt) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018068120A1 (pt) * | 2016-10-13 | 2018-04-19 | Proteimax Biotecnologia Ltda | Uso de composto, intermediário de síntese, composição farmacêutica e método terapêutico neuromodulador |
WO2018068119A1 (pt) * | 2016-10-13 | 2018-04-19 | Proteimax Biotecnologia Ltda | Uso de composto, composição farmacêutica e método terapêutico curativo ou profilático de convulsões |
WO2018209415A1 (pt) | 2017-05-15 | 2018-11-22 | Remer Consultores Assessoria Empresarial Ltda. | Composto, intermediário de síntese, uso, composição farmacêutica e método terapêutico neuromodulador |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070213302A1 (en) | 2006-03-10 | 2007-09-13 | Jenrin Discovery | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
WO2011011847A2 (en) | 2009-07-31 | 2011-02-03 | Sociedade Beneficiente De Senhoras Hospital Sirio Libanes | Pharmaceutical composition for treating medical conditions and a method for treating alimentary disorders and related diseases |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7257562B2 (en) * | 2000-10-13 | 2007-08-14 | Thallion Pharmaceuticals Inc. | High throughput method for discovery of gene clusters |
US7235651B2 (en) * | 2001-12-26 | 2007-06-26 | Cubist Pharmaceuticals, Inc. | Genes and proteins involved in the biosynthesis of lipopeptides |
-
2012
- 2012-07-13 BR BRBR102012017421-9A patent/BR102012017421A2/pt not_active IP Right Cessation
-
2013
- 2013-07-12 US US14/412,781 patent/US9796760B2/en active Active
- 2013-07-12 CN CN201380047844.5A patent/CN104619333B/zh active Active
- 2013-07-12 WO PCT/BR2013/000251 patent/WO2014008567A1/pt active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070213302A1 (en) | 2006-03-10 | 2007-09-13 | Jenrin Discovery | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
WO2011011847A2 (en) | 2009-07-31 | 2011-02-03 | Sociedade Beneficiente De Senhoras Hospital Sirio Libanes | Pharmaceutical composition for treating medical conditions and a method for treating alimentary disorders and related diseases |
Non-Patent Citations (5)
Title |
---|
CARLOS FIORAVANTI ET AL.: "Vôos de fênix: Fragmento de proteína ligado ao controle da pressão arterial pode ajudar a emagrecer e a tratar dependencia quimica.", PESQUISA FAPESP., 2008, pages 44 - 47, XP055186890 * |
GOMES I ET AL.: "Novel endogenous peptide agonists of cannabinoid receptors.", THE FASEB JOURNAL., vol. 23, no. 9, 2009, pages 3020 - 3029, XP055186735 * |
RIOLI V ET AL.: "Novel natural peptide substrates for endopeptidase 24.15, neurolysin, and angiotensin-converting enzyme.", J BIOL CHEM., vol. 278, no. 10, 2003, pages 8547 - 55, XP002353088 * |
See also references of EP2878306A4 * |
VANESSA RIOLI; FABIO C. GOZZO; ANDREA S. HEIMANN; ALESSANDRA LINARDI; JOSE E. KRIEGER; CLAUDIO S. SHIDA; PAULO C. ALMEIDA; STEPHEN, NOVEL NATURAL PEPTIDE SUBSTRATES FOR ENDOPEPTIDASE 24.15 NEUROLYSIN, AND ANGIOTENSIN-CONVERTING ENZYME |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018068120A1 (pt) * | 2016-10-13 | 2018-04-19 | Proteimax Biotecnologia Ltda | Uso de composto, intermediário de síntese, composição farmacêutica e método terapêutico neuromodulador |
WO2018068119A1 (pt) * | 2016-10-13 | 2018-04-19 | Proteimax Biotecnologia Ltda | Uso de composto, composição farmacêutica e método terapêutico curativo ou profilático de convulsões |
US10933113B2 (en) | 2016-10-13 | 2021-03-02 | Proteimax Biotecnologia Ltd. | Use of a compound, pharmaceutical composition, and therapeutic method for the treatment or prevention of convulsions |
WO2018209415A1 (pt) | 2017-05-15 | 2018-11-22 | Remer Consultores Assessoria Empresarial Ltda. | Composto, intermediário de síntese, uso, composição farmacêutica e método terapêutico neuromodulador |
Also Published As
Publication number | Publication date |
---|---|
BR102012017421A2 (pt) | 2015-04-14 |
CN104619333A (zh) | 2015-05-13 |
US9796760B2 (en) | 2017-10-24 |
US20150291662A1 (en) | 2015-10-15 |
CN104619333B (zh) | 2020-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Finn et al. | Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice | |
Yazaki et al. | Oral ingestion of collagen hydrolysate leads to the transportation of highly concentrated Gly-Pro-Hyp and its hydrolyzed form of Pro-Hyp into the bloodstream and skin | |
Hoefig et al. | Thyronamines and derivatives: physiological relevance, pharmacological actions, and future research directions | |
Noda et al. | Sodium sensing in the brain | |
Stengel et al. | The role of nesfatin‐1 in the regulation of food intake and body weight: recent developments and future endeavors | |
JP6086528B2 (ja) | 長期のインビボ有効性を有する成長ホルモン | |
Donkers et al. | NTCP deficiency in mice protects against obesity and hepatosteatosis | |
Gnocchi et al. | Emerging role of thyroid hormone metabolites | |
Stengel et al. | Abdominal surgery inhibits circulating acyl ghrelin and ghrelin-O-acyltransferase levels in rats: role of the somatostatin receptor subtype 2 | |
Wang et al. | Endostatin prevents dietary-induced obesity by inhibiting adipogenesis and angiogenesis | |
Lin et al. | COL1A1 as a potential new biomarker and therapeutic target for type 2 diabetes | |
Seitz et al. | Hepatic Rab24 controls blood glucose homeostasis via improving mitochondrial plasticity | |
Tharp et al. | Prevention of gallbladder hypomotility via FATP2 inhibition protects from lithogenic diet-induced cholelithiasis | |
JP2015013872A (ja) | 脂質動員特性を有する糖タンパク質およびその治療的使用法 | |
WO2014008567A1 (pt) | Peptídeo modificado, ligante de receptores cb, kit, processo in vitro para avaliação de ligação a receptores cb, usos, composição farmacêutica para modular a atividade de receptores cb | |
Carlson et al. | fMLP induces Hsp27 expression, attenuates NF-κB activation, and confers intestinal epithelial cell protection | |
Nagy et al. | Selegiline reduces adiposity induced by high‐fat, high‐sucrose diet in male rats | |
JP5875190B2 (ja) | メチルグリオキサール−スカベンジング化合物ならびに疼痛および/または痛覚過敏の予防および治療のためのその使用 | |
Lin et al. | Endoplasmic reticulum stress is involved in DFMO attenuating isoproterenol-induced cardiac hypertrophy in rats | |
WO2020041673A1 (en) | Compositions and methods related to cholic acid-7-sulfate as a treatment for diabetes | |
Rodriguez et al. | Testosterone reduces metabolic brown fat activity in male mice | |
Xia et al. | Mapping the response of human fibroblast growth factor 21 (FGF21) promoter to serum availability and lipoic acid in HepG2 hepatoma cells | |
Laurila et al. | Pleiotropic effects of secretin: a potential drug candidate in the treatment of obesity? | |
Fang et al. | Emerging roles of kisspeptin/galanin in age-related metabolic disease | |
Linlin et al. | Comprehensive analyses of annexins in naked carp (Gymnocypris przewalskii) unveil their roles in saline-alkaline stress |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13816344 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14412781 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013816344 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015000388 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015000388 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150108 |